BioAge Labs unveiled full Phase 1 data for BGE-102, its oral, brain-penetrant NLRP3 inhibitor, at the American Heart Scientific Sessions 2026. The results cover

BioAge Labs unveiled full Phase 1 data for BGE-102, its oral, brain-penetrant NLRP3 inhibitor, at the American Heart Scientific Sessions 2026. The results covered healthy volunteers and obesity patients with elevated inflammation, marking pipeline progress.